[Comparative studies on the bioavailability of various drug forms of phenylbutazone and clofezone (Perclusone)].
The bioavailability (BA) of phenylbutazone and clofezone preparations had been determined in patients suffering from rheumatic diseases. Clofezone is a compound preparation of phenylbutazone and clofexamide, with which the phenylbutazone portion amounts to 49%. In spite of an equivalent dosage (0.4 g phenylbutazone or 0.8 g clofezone, resp.) significant differences in the phenylbutazone-serum level profile had partly been stated after the application of different kinds of the preparation of both the drugs. The oral administrations (phenylbutazone dragées, Perclusone capsules) resulted in a prompt resorption; the plateau values of the phenylbutazone concentration in serum had already been completed after 2-3 h. The resorption from suppositories was decreased. The serum level maximum with phenylbutazone suppositories occurred after 6 h, with Perclusone suppositories after 24 h only. Compared to the phenylbutazone i.v. injection, the phenylbutazone dragées proved a complete substance uptake into the systemic circulation, whereas a relative BA of 65% has been determined for Perclusone capsules. The BA of the phenylbutazone suppositories amounted to 67%, those of the Perclusone suppositories to 41%.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001682:Biological Availability; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010653:Phenylbutazone / Q000031:analogs & derivatives* / Q000378:metabolism*; D013488:Suppositories
D013488:Suppositories; D010653:Phenylbutazone
Vergleichende Untersuchungen zur Bioverfügbarkeit verschiedener Arzneiformen von Phenylbutazon und Clofezon (Perclusone).